Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.22. Hemispherx BioPharma shares last traded at $0.22, with a volume of 303,688 shares.
Hemispherx BioPharma Price Performance
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
See Also
- Five stocks we like better than Hemispherx BioPharma
- What is the Shanghai Stock Exchange Composite Index?
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
